Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)

Gongwin Biopharm Holdings Revenue

Gongwin Biopharm Holdings had revenue of 9.47M TWD in the quarter ending March 31, 2026, with 24.09% growth. This brings the company's revenue in the last twelve months to 38.28M, up 11.86% year-over-year. In the year 2025, Gongwin Biopharm Holdings had annual revenue of 36.45M with 13.75% growth.

• Revenue (ttm): 38.28M
• Revenue Growth: +11.86%
• P/S Ratio: 231.25
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 8.85B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	36.45M	4.41M	13.75%
Dec 31, 2024	32.04M	13.13M	69.39%
Dec 31, 2023	18.92M	17.77M	1,554.86%
Dec 31, 2022	1.14M	-	-
Dec 31, 2021	1.14M	310.00K	37.21%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 30, 2026

Data Sources Report a data error